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Background: Misregulation of the PTGS (prostaglandin endoperoxide synthase, also known as cyclooxygenase or
COX) pathway may lead to the accumulation of pro-inflammatory signals, which constitutes a hallmark of cancer. To
get insight into the role of this signaling pathway in colorectal cancer (CRC), we have characterized the transcriptional
and epigenetic landscapes of the PTGS pathway genes in normal and cancer cells.
Results: Data from four independent series of CRC patients (502 tumors including adenomas and carcinomas and 222
adjacent normal tissues) and two series of colon mucosae from 69 healthy donors have been included in the study.
Gene expression was analyzed by real-time PCR and Affymetrix U219 arrays. DNA methylation was analyzed by bisulfite
sequencing, dissociation curves, and HumanMethylation450K arrays. Most CRC patients show selective transcriptional
deregulation of the enzymes involved in the synthesis of prostanoids and their receptors in both tumor and its
adjacent mucosa. DNA methylation alterations exclusively affect the tumor tissue (both adenomas and carcinomas),
redirecting the transcriptional deregulation to activation of prostaglandin E2 (PGE2) function and blockade of other
biologically active prostaglandins. In particular, PTGIS, PTGER3, PTGFR, and AKR1B1 were hypermethylated in more than
40 % of all analyzed tumors.
Conclusions: The transcriptional and epigenetic profiling of the PTGS pathway provides important clues on the
biology of the tumor and its microenvironment. This analysis renders candidate markers with potential clinical
applicability in risk assessment and early diagnosis and for the design of new therapeutic strategies.
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There is strong evidence associating inflammation with
cancer [1–3]. Risk factors such as tobacco smoke, high-fat
diet, and chronic infection are correlated with chronic
inflammation [4], and the tumor-microenvironment itself
has an intrinsic inflammatory component [1, 2]. Prosta-
noids are signaling molecules with important pro- and anti-
inflammatory roles synthesized from arachidonic acid via
the PTGS (prostaglandin endoperoxide synthase, also
known as cyclooxygenase or COX) pathway. Deregulation
of the enzymes of this pathway during inflammatory* Correspondence: map@imppc.org
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levels of the different prostanoids [5–7].
The association of genetic polymorphisms in PTGS
pathway genes and colorectal cancer risk and survival
[8–11] supports its involvement in the etiology of the
disease. PTGS2 (also known as COX-2), one of the key
enzymes of this pathway, is frequently overexpressed in
colorectal tumors, which results in overproduction of
the downstream metabolite prostaglandin E2 (PGE2).
Both, PTGS2 expression and PGE2 levels have been
shown to correlate with metastasis and poor prognosis
in colorectal cancer patients [12, 13, 7, 14–16]. A re-
cent study has also highlighted the participation of
PGE2/PTGS2 signaling during development of che-
moresistance [17].rticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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(NSAIDs) are able to inhibit cyclooxygenase activity and
have been shown to reduce the risk and improve the out-
come of colorectal cancer (CRC) and other gastrointestinal
tumors [18–23]. However, their prescription for chemopre-
vention of colorectal cancer is restricted to high-risk indi-
viduals due to an associated increased risk of hemorrhagic
strokes and gastrointestinal complications [24, 22]. PTGS2-
specific inhibitors (coxibs) show lower gastrointestinal
toxicity, but an increased risk of cardiovascular compli-
cations [25, 22].
Transformation of the colorectal tissue is character-
ized by the successive acquisition of genetic and epigen-
etic alterations that confer advantageous traits for
tumorigenesis initiation and cancer progression [26].
Among these, DNA methylation alterations are known
to be involved [27–30]. Whereas DNA hypomethylation
of repetitive regions and oncogenes increases genomic
instability and facilitates aberrant re-expression of
imprinted genes, promoter CpG island DNA hyperme-
thylation results in the acquisition of a repressed chro-
matin state and consequent gene silencing. This process
is known to underlie the silencing of several tumor-
suppressor genes in cancer, including APC and p16,
which contribute to the acquisition and maintenance of
an oncogenic state [29, 30].
Numerous components of this pathway have been
found deregulated by DNA hypermethylation in cancer
(reviewed in [31]). However, to our knowledge, no study
has addressed how DNA methylation of multiple genes
may affect the overall prostanoid production in the trans-
formed colorectal tissue, nor in other types of cancer.
Here, we have investigated transcriptional and epigenetic
profiles of the PTGS pathway in four series of colorectal
cancer patients (Additional file 1: Table S1). We report a
global deregulation of this pathway in both the colonic
mucosae and the tumor and pinpoint a set of features that
might be of value as new diagnostic markers and/or as
therapeutic targets in colorectal cancer patients.
Results
Expression profiling of the PTGS pathway in colorectal
tissue
Previous reports have shown that the PTGS pathway is
frequently deregulated in a number of cancers reviewed
in [31]. While some of its major pathology-related fea-
tures have already been studied in depth, including the
overexpression of PTGS2 during inflammation and
tumorigenesis [32, 6], the complete picture of the regula-
tory state of this pathway in CRC remains elusive.
To gain a first glimpse at the changes the PTGS pathway
undergoes during colorectal tumorigenesis, we analyzed
gene expression levels in a series of nine CRC tumors and
adjacent mucosae. Even though the samples presentedheterogeneous expression profiles, our results show that
the transcriptional profile of the PTGS pathway is markedly
altered during tumorigenesis, presenting downregulation of
many genes in the majority of tumors (Fig. 1a). On the
other hand, we observed overall increased expression of
PGE2 synthases (especially of PTGES2 and PTGES3) (gene
nomenclature is shown in Additional file 1: Table S2).
We then extended our study by applying microarray
expression analysis to a cohort of 98 CRC patients
(Table 1). In order to identify possible disease-related
features in the adjacent tissues of patients, this analysis
included the colonic tissues from a control cohort
comprising 50 healthy individuals. Following the trend
registered in our test cohort, we observed frequent
downregulation of eight genes and recurrent overex-
pression of all PGE2 synthases (PTGES, PTGES2 and
PTGES3, Tukey’s HSD test P < 0.0001) in CRC tumors
(Fig. 1b, Table 2). In accordance with our initial analysis
and previous reports [33, 34], PTGS2 showed a heteroge-
neous pattern, being only overexpressed in a subset of
tumors (Fig. 1b, Table 2, Tukey’s HSD test P = 0.0091).
PTGS2 protein analysis revealed an equally variable ex-
pression pattern (data not shown).
Noteworthy, we observed significant alterations in the
transcriptional profile of mucosae adjacent to tumors
in comparison to normal mucosae obtained from healthy
donors, with many genes showing a rebound effect
during the tumorigenic process. Specifically, PTGES2 and
PTGES3 tended to be downregulated in adjacent mucosae
(Tukey’s HSD test P = 0.0158 and P < 0.0001, respectively),
but overexpressed in tumors (P < 0.0001 for both) (Fig. 1b,
Table 2). The opposite trend was observed with PTGER4,
PTGDS, PTGER3, PTGIS, PTGFR, and PTGS1 genes,
which showed overexpression in the adjacent non-tumor
tissue, followed by downregulation in the tumor. PTGS2
was found significantly overexpressed in adjacent mucosae
from patients (Tukey’s HSD test P < 0.0001). The observed
trends were even more evident when we examined a panel
of five CRC cell lines (Additional file 1: Figure S1A).
Overall, these results demonstrate an abnormal behavior
of most of the genes of the PTGS pathway not only in tu-
mors, but also in the non-tumor adjacent tissue of CRC
patients. Even though the altered expression of many
genes is maintained or even exacerbated in tumors, a sub-
set overturns its deregulation, reversing the expression
levels in the cancer tissue to either upregulation (i.e.,
PTGES3) or a strong downregulation (i.e., PTGIS).
DNA methylation profiling of the PTGS pathway in
colorectal tissue
Previous reports from our lab and others have shown
that PTGS pathway genes can undergo epigenetic silen-
cing during cancer, in particular through promoter-
associated-CpG island DNA methylation [31, 35]. For
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Fig. 1 PTGS pathway expression profiling in colorectal cancer. a Preliminary analysis of a set of nine colorectal tumors by quantitative real-time
PCR reveals overall imbalance of gene expression regulation in comparison with adjacent normal colonic mucosae, being most of the genes
downregulated. Exceptionably, the expression of genes responsible for PGE2 biosynthesis is maintained or increased. Absolute expression levels
were calculated by the delta Ct method (see “Methods” section). Relative expression corresponds to tumor/adjacent mucosa ratio. b Microarray
analysis performed on a cohort of 98 CRC patients (both tumor and adjacent mucosae) and 50 matched healthy donors. As in a, most genes are
deregulated, with marked differences not only between tumors and their adjacent normal tissues, but also between normal tissues from patients
and healthy individuals
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methylation could be the mechanism responsible for the
repression of these genes in CRC, having combined
three independent sets of samples and two DNA
methylation detection methods.
Dissociation curve analysis was applied to detect
changes in the DNA methylation content of PTGS path-
way genes in 64 CRC patients, together with five CRC
cell lines (Fig. 2a). In addition, we assessed the DNA
methylation profiles of 98 CRC patients (tumor and
adjacent mucosa pairs) and 50 healthy individuals with
the InfiniumMethylation450K platform (Fig. 2b, Table 2).
Both methodologies revealed the same trends, being
the AKR1B1-, PTGIS-, PTGFR-, and PTGER3-associated
CpG islands, the ones altered at a higher rate (Fig. 2d).Similar results were observed in the publically available
datasets from the TCGA (Fig. 2c, d).
Next, we wondered whether the methylation abnor-
malities occurred early in tumor progression. We tack-
led this issue by analyzing data available from a recent
study in which DNA methylation profiles were also ana-
lyzed with the same platform in normal colonic mucosae,
adenomas, and carcinomas [36]. Interestingly, the methyla-
tion profiles of adenomas mimicked those of carcinomas,
indicating the contribution of DNA methylation alterations
early in tumorigenesis (Additional file 1: Figure S2).
Once again, normal mucosa from CRC patients showed
no alterations when compared with healthy individuals,
confirming our previous observations with the Colo-
nomics series.
Table 1 Baseline characteristics of healthy donors and CRC
patients from the Colonomics study
Healthy donors (n = 50)
Gender
Male 27 (54 %)
Female 23 (46 %)
Median age (years, range) 63 (25–88)
Site
Right 27 (54 %)
Left 23 (46 %)
Cases (n = 98)
Gender
Male 71 (72.4 %)
Female 27 (27.6 %)
Median age (years, range) 71 (43–87)
Site
Right 38 (38.8 %)
Left 60 (61.2 %)
Stage
II A 90 (91.8 %)
II B 8 (8.2 %)
Recurrence
No relapse 76 (77.6 %)
Relapse 22 (22.4 %)
Follow-up, median time (months, range) 67.8 (24.8–136.9)
Table 2 Summary table with P values for the comparisons of
tumors and normal mucosae from patients and healthy donors
from the Colonomics study
Gene expression DNA methylation
N vs. A A vs. T ANOVA N vs. A A vs. T ANOVA
AKR1B1 0.9482 0.0171 0.007 0.7758 <0.0001 <0.0001
HPGD <0.0001 <0.0001 <0.0001 – – 0.076
PTGDR 0.2583 <0.0001 <0.0001 – – 0.1083
PTGDS <0.0001 <0.0001 <0.0001 – – 0.0837
PTGER1 0.7856 0.0341 0.0414 0.8720 0.0052 <0.0001
PTGER2 <0.0001 <0.0001 <0.0001 – – 0.3878
PTGER3 <0.0001 0.0037 <0.0001 0.8859 <0.0001 <0.0001
PTGER4 0.0005 <0.0001 <0.0001 – – 0.9691
PTGES <0.0001 <0.0001 <0.0001 0.6580 0.0222 0.0147
PTGES2 0.0158 <0.0001 <0.0001 – – 0.6959
PTGES3 <0.0001 <0.0001 <0.0001 – – 0.0545
PTGFR <0.0001 <0.0001 <0.0001 0.7811 <0.0001 <0.0001
PTGIR 0.0005 0.0086 0.0003 0.9245 <0.0001 <0.0001
PTGIS <0.0001 <0.0001 <0.0001 0.9392 <0.0001 <0.0001
PTGS1 <0.0001 <0.0001 <0.0001 0.0118 <0.0001 <0.0001
PTGS2 <0.0001 0.0091 <0.0001 0.9866 <0.0001 <0.0001
TBXA2R <0.0001 <0.0001 <0.0001 0.0362 0.0029 <0.0001
ANOVA test was applied to determine significant differences among the three
types of sample. Genes with significant differences (P < 0.05) were further
evaluated with Tukey’s range test for differences of normal colonic mucosae
from healthy donors (N) versus adjacent tissue from CRC patients (A), and of
adjacent mucosae (A) versus CRC tumors (T)
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line HCT116-DKO [37], which presented reconstitution
of the expression of most of these genes, supporting our
hypothesis of an epigenetic silencing mechanism—DNA
methylation—behind the observed transcriptional down-
regulation in CRC (Additional file 1: Figure S1B).
Profiling of the PTGS pathway in colorectal cancer
progression
DNA methylation is not the only possible mechanism re-
sponsible for gene downregulation and silencing. For this
reason, we further interrogated the TCGA database for
DNA sequence alterations in PTGS pathway genes. This
analysis all included all indels, large deletions and amplifica-
tions detected in PTGS pathway genes in CRC tumors.
Overall, approximately a quarter of the analyzed tumors
presented a mutation in at least one of the genes, but when
analyzed individually, none of the genes revealed a high fre-
quency of deleterious mutations in colorectal tumors. Fur-
thermore, no deleterious mutations have been detected in
any of the PGE2 synthases, neither in the receptors
PTGER2 and TBXA2R (Additional file 1: Figure S3A).
Interestingly, although the observed mutation rates are verylow, there still seems to be significant poor prognosis asso-
ciated with mutations in PTGFR, one of the genes most
predominantly hypermethylated and downregulated in
colorectal tumors (Additional file 1: Figure S3B).
Considering that primary tumors from closely related
tissues tend to share common molecular signatures, we
postulated that the methylation patterns found in colo-
rectal cancer could be also found in other cancer types.
Indeed, not only colorectal, but also liver, stomach, and
pancreas tumors present high rates of hypermethylation
of PTGIS, AKR1B1, PTGER3, and PTGFR (Fig. 2e). Our
data together with data from TCGA suggest that
promoter-associated CpG island DNA methylation is the
major mechanism involved in the deregulation of the
PTGS pathway in colorectal and other types of cancer in
the gastrointestinal tract.
Gene expression profiles of normal mucosae distinguish
patients from healthy donors
Our comparisons of tumors with adjacent mucosae and
normal colonic tissue from healthy donors revealed dif-
ferences in both gene expression and DNA methylation
levels. To elucidate if the observed alterations could
Fig. 2 (See legend on next page.)
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Fig. 2 PTGS pathway DNA methylation profiling in colorectal cancer. a Dissociation curve analysis of CRC patients and cell lines. A total of 64
patients (tumor and adjacent mucosae pairs) and five cell lines were analyzed with this method. Cell lines were compared to an unmethylated normal
tissue. b DNA methylation beta values quantified with InfiniumMethylation450K arrays for a cohort of 98 CRC patients (both tumor and adjacent
mucosae) and 50 matched healthy donors. Unlike gene expression, adjacent normal tissue of CRC patients displays normal methylation profiles
compared with the mucosae from healthy donors, while tumors show a large number of abnormalities. c Unsupervised clustering analysis of the DNA
methylation levels of 254 CRC tumors from in the Cancer Genome Atlas (TCGA). AKR1B1, PTGIS, and PTGER3 were the genes exhibiting the highest
rates of hypermethylation in CRC. d DNA methylation analysis by dissociation curve and InfiniumMethylation450K array (Colonomics study and TCGA)
provide similar results. White to red color scale represents the minimum and maximum percentage of hypermethylated tumors, respectively. Methylation
status of the PTGS pathway genes in a panel of six colorectal cancer cell lines is represented. Genes frequently methylated in CRC tumors are also
methylated in the analyzed cell lines. Red represents methylation in >75 % of the CpG sites. e Proportion of tumors with DNA methylation of the PTGS
pathway genes in different cancer types. Data were obtained from TCGA
Cebola et al. Clinical Epigenetics  (2015) 7:74 Page 6 of 11provide a signature for each type of tissue, we applied
unsupervised hierarchical clustering analysis (see Sup-
plementary Methods section in Additional file 1 for
more details) to the data obtained for 98 patients and
50 healthy donors. Our analysis revealed that tumors
present a different profile for both features, forming a
separate cluster in both analyses, whereas adjacent mu-
cosae from patients can only be distinguished from nor-
mal mucosae in terms of gene expression, being their
DNA methylation profiles indistinguishable (Fig. 3). In
all cases, the Jaccard similarity index obtained as a re-
sult of the bootstrap resampling was above 0.75, indi-
cating the clusters’ stability.Gene expression
0.860
0.945
0.835
Fig. 3 PTGS pathway gene expression and DNA methylation alterations du
expression and DNA methylation levels for the 98 CRC patients and 50 hea
for sample clustering is indicated next to tree branches. Expression pattern
mucosae from patients (blue), in comparison to healthy donor colonic muc
DNA methylation profilesDeregulation of the PTGS pathway in colorectal cancer
and clinicopathological correlates
As we have shown above, tumors exhibited distinctive sig-
natures of both gene expression and DNA methylation,
but some differences were also observed within tissue
types. Therefore, we analyzed clinicopathological corre-
lates of gene expression and DNA methylation signatures
to determine whether these differences could be associ-
ated with features of the patients. Mucosae from control
patients did not show any difference regarding age, sex, or
location for both gene expression and DNA methylation
(Additional file 1: Tables S3 and S4), except for PTGFR,
that was slightly more methylated in older individuals.DNA methylation
0.778
0.765
0.952
ring colorectal tumorigenesis. Hierarchical clustering analysis of gene
lthy donors from the Colonomics dataset. The Jaccard similarity index
s are markedly different not only in tumors (red), but also in adjacent
osae (green). In contrast, only tumors cluster separately in terms of
Cebola et al. Clinical Epigenetics  (2015) 7:74 Page 7 of 11This trend was also observed in the adjacent tissue of
cancer patients. Strikingly, methylation differences were
observed in eight genes between left and right side nor-
mal tissues of patients, but only one of them (PTGDS)
also showed expression differences (hypomethylated
and overexpressed in right colon versus left colon)
(Additional file 1: Tables S3 and S4). Principal compo-
nent analysis of DNA methylation data revealed that pa-
tients with tumors in the left side of the colon tend to
have distinctive methylation profiles, while those with tu-
mors in the right side overlap with both right and left co-
lonic mucosa of controls (Additional file 1: Figure S4).
Tumor molecular profiles showed few associations
with clinicopathological variables, and these included
downregulation of PTGDR and PTGS1 in older patients,
overexpression of PTGER2, and hypermethylation of
PTGS2 in right side tumors as compared with left colon
(Additional file 1: Tables S3 and S4). Regarding prognosis,
we found neither gene expression nor DNA methylation
altered signatures as robust predictors of disease-free or
overall survival (data not shown). Nevertheless, a quick
analysis of gene expression data released in public data-
bases suggests that the expression levels of many genes of
the PTGS pathway are associated with poor prognosis
(Additional file 1: Figure S5). Availability of follow-up
data from large cohorts in the near future should clarify
this issue.
Discussion
In cancer, the most frequent genetic alterations are
found in a number of pathways that regulate crucial cel-
lular processes [38, 39]. However, the majority of studies
are focused on the role of individual genes, overlooking
their biological context. The PTGS metabolic pathway is
aberrantly regulated in cancer, being the overexpression
of PTGS2 a major feature of many tumor types [6].
Nevertheless, this study and others [33, 40, 41] have
shown that only a fraction of CRC present PTGS2 over-
activation. This observation together with the fact that
PTGS2 targeting is associated with increased cardiovas-
cular risk [24, 25] raises the necessity to develop better
strategies to specifically target this signaling pathway be-
fore and after tumor appearance.
It is well established that DNA methylation alterations
are a frequent feature of many types of cancer, including
colorectal cancer [29, 30, 28]. A noteworthy work from
Grady and colleagues has demonstrated genome-wide
aberrant DNA methylation patterns in early stages of
colorectal cancer progression [36]. In particular, there is
strong evidence that the PTGS pathway is deregulated at
both transcriptional and epigenetic levels in colorectal
cancer (reviewed in reference [31]). Nevertheless, the
overall landscape of the PTGS pathway in CRC had not
been outlined yet. In line with these observations, we havefocused this work in the differential DNA methylation of
PTGS pathway genes in CRC, having profiled data from a
total of 502 tumors. This revealed up to 12 genes that are
suppressed in CRC (Fig. 3), including genes that had been
previously found misregulated in cancer, such as HPGD,
PTGIS, PTGER3, and AKR1B1 [31].
Even though we analyzed the DNA methylation contents
of tumors from four independent collections and applied
two different methods, there was remarkable consistency
among all datasets. The gene PTGER1 was the only one
showing clear discrepancies, which we believe are due to
the different location of the array probes and the oligonu-
cleotides used in dissociation curve analysis.
We have found four genes (AKR1B1, PTGIS, PTGER3,
PTGFR) hypermethylated in a high proportion of all ana-
lyzed tumors (70, 63, 45, and 50 %, respectively), suggest-
ing that DNA methylation is an important mechanism
involved in the deregulation of this pathway in CRC. Even
though downregulation of PTGER3 and AKR1B1 had been
previously reported [42–44], this is the first time that their
DNA hypermethylation is reported in CRC, whereas the
epigenetic silencing of PTGIS and PTGFR had been previ-
ously observed [35, 45]. Importantly, the methylation ab-
normalities appear to occur early in tumorigenesis, as
their frequency was similar in adenomas and carcinomas
(Additional file 1: Figure S2). This result, together with
the absence of DNA methylation abnormalities in the ad-
jacent normal tissue of CRC patients, suggests that epi-
genetic alterations may have a critical role in the
overriding of the pro-inflammatory status towards a ma-
lignant phenotype.
We also interrogated the TCGA database for mutations
in these genes, having found little evidence of downregula-
tion of PTGS pathway genes in CRC due to genetic alter-
ations. These results further support DNA methylation as
a major gene silencing mechanism involved in this
process. Still, other mechanisms cannot be fully discarded,
particularly for AKR1B1 and PTGFR, whose expression is
not recovered in DNMT-deficient cells.
Our experimental design included the analysis of co-
lonic mucosae collected from healthy individuals, which
allowed us to detect pre-oncogenic alterations already
present in the adjacent mucosae of CRC patients. We
observed a marked hyperactivation of the pathway at the
expression level in adjacent mucosae from patients,
which likely reflects a highly inflammatory state of the
tissue (Fig. 4). Whether this inflammatory state is cause
or consequence of the tumor development remains to be
fully understood.
Our results also suggest that the establishment of an in-
flammatory state in this tissue precedes and possibly con-
tributes to the epigenetic alterations we observe in tumors.
In this regard, a connection between PTGS signaling and
epigenetic changes has been proposed [46, 47]. Xia and
Fig. 4 Model for PTGS pathway deregulation during colorectal tumorigenesis. Inflammatory processes, including overactivation of PTGS signaling,
are present in the colonic mucosae during, and possibly before, tumor development. In the tumor, promoter hypermethylation and other
mechanisms contribute to the repression of several prostanoid-specific synthases and membrane receptors. This leads to the prevalence of
PGE2 as the major prostanoid in tumor cells, whose downstream actions may include evasion of apoptosis, tumor growth, angiogenesis, and
metastasis
Cebola et al. Clinical Epigenetics  (2015) 7:74 Page 8 of 11collaborators found compelling evidences supporting a role
of PGE2 promoting gene silencing by DNA methylation in
CRC [47].
Even though our analysis has only been focused on
transcriptional and epigenetic profiling of a series of
CRC tumors, our data strongly suggests that colorectal
cancers present a strong bias towards PGE2 production
and pro-oncogenic signaling in detriment of the other
prostanoids (Fig. 4). The overall deregulation of the
pathway results in protection of the PGE2 biosynthetic
pathway (PTGES, PTGES2, and PTGES3) and strong
downregulation of HPGD, the responsible for PGE2 deg-
radation in the cytosol. This is concordant with PGE2
being the major prostanoid in tumor microenvironments
[6, 48] and fits previous observations in ApcMin trans-
genic mice, where deletion of PTGER1, PTGER2, and
PTGER4 inhibits the development of CRC [49–51].
Interestingly, each one of the PGE2 receptors displayed a
distinctive behavior. PTGER3 and PTGER4 were upregu-
lated in adjacent mucosa, which could indicate the permis-
siveness of the host tissue to PTGS signaling. Both
receptors appear to have similar roles in stromal regulation
[52], but show different behaviors in the tumor: PTGER3 is
the only receptor whose overexpression is maintained in
the tumor tissue (Fig. 1b). This could be related with itsreported role in increasing tumor growth, as opposed to
the rest of the receptors [53]. PTGER2 showed consistent
downregulation in both normal and tumor tissue.
A recent study has shown that in vivo administration
of celecoxib (an inhibitor of PTGS2) abrogates chemore-
sistance in xenografted tumors derived from a patient
who was resistant to chemotherapy. These results
strongly suggest the participation of the PTGS/PGE2 sig-
naling axis in the reactivation of cancer stem cells, a
major cause of treatment failure [17].
Our integrative approach has contributed to explore the
intricacies of the PTGS pathway in colorectal cancer, re-
vealing a dual disruption: the adjacent non-tumor tissue of
colorectal cancer patients shows global transcriptional up-
regulation of the PTGS pathway; whereas, cancer cells re-
strict the hyperactivation towards PGE2 signaling, which is
achieved by epigenetic silencing of competing eicosanoid
synthases and receptors, even in early stages of tumor pro-
gression. The possible involvement of epigenetic alterations
in malignant cell transformation within a pro-inflammatory
microenvironment releases new candidate biomarkers for
prevention and early diagnosis, as well as potential new
therapeutic targets. Taking into account the likely contribu-
tion of this pathway to the etiology and progression of
the disease, further functional studies are required to
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tion and signaling in both normal and malignant cells.
The ability to modulate this pathway may constitute a
powerful tool to prevent and eventually treat colorectal
cancer.
Finally, the influence of environmental factors cannot
be excluded from the etiology of CRC. As a metabolic
pathway, the PTGS pathway signaling is a result of an
individual’s metabolic state, being directly responsive to
environmental exposures. On the other hand, diet and
lifestyle factors are also known to contribute to aberrant
epigenetic signatures in colorectal cancer (reviewed in
[54–56]). In an omics era, patients’ clinical pictures and
response to therapy should be seen as the result of their
unique genome, epigenome, transcriptome, proteome,
metabolome, as well as of their interactome and expo-
some [56, 57]). The emerging concept of molecular
pathological epidemiology (MPE) [57], which aims to inte-
grate all contributing factors in one discipline, should bring
new queues of personalized medicine to CRC patients. Fu-
ture studies should aim to go further and integrate studies
like ours with other layers of information such as diet in
order to better prevent and treat cancer patients.
Conclusions
This study shows that the PTGS signaling pathway dis-
plays a pro-inflammatory molecular signature in the
non-tumor colonic mucosa of colorectal cancer patients.
Noteworthy, in colorectal adenomas and carcinomas,
epigenetic mechanisms (namely DNA hypermethylation)
redirect the transcriptional deregulation of the non-
tumor environment towards selective activation of PGE2
function and blockade of other biologically active prosta-
glandins. These results have important implications for
the proper design and application of preventive and
therapeutic strategies targeting prostaglandin metabol-
ism. The large arsenal of available agonists and antag-
onists of prostaglandins demand an individualized
analysis of the PTGS pathway not only in patients, but
also in individuals at risk of developing CRC.
Availability of supporting data
All sequencing and array data supporting the results of this
article are available through Gene Expression Omnibus
with accession numbers GSE44076 and GSE48684, and the
TCGA data through cBioportal (www.cbioportal.org).
Methods
Patients
Four series of colorectal cancer patients were used in this
study (Additional file 1: Table S1). The first series included
a total of 64 colorectal cancer patients from the Institut
Català d’Oncologia (L’Hospitalet, Barcelona, Spain) and
Hospital Germans Trias i Pujol (Badalona, Barcelona,Spain). Gene expression and DNA methylation analyses
were performed in tumor and adjacent normal mucosae as
described below. The most important clinicopathological
information of patients and healthy controls is presented in
Additional file 1: Table S5. The study was approved by the
Hospital Germans Trias i Pujol ethical committee. The in-
dividuals gave their written informed consent.
Data from the Colonomics project (www.colonomics.org)
was used as second series and comprised 98 colon tu-
mors and paired pathologically adjacent normal mucosa
samples (minimum distance of 10 cm from the tumor).
Pathologists confirmed all colon cancer diagnoses and
selected fresh tissue samples from tumor and normal
mucosa taken from the proximal resection margin. Fifty
tissue samples of non-cancer colon mucosa, with no
adenomas and no family cancer history reported, were
obtained through colonoscopy. The most important
clinicopathological information of patients and healthy
donors is presented in Table 1.
Data for a third cohort of 254 colorectal tumors, 38 of
which with adjacent tissues, were obtained from The
Cancer Genome Atlas (TCGA) (www.cancergenome.nih.
gov). DNA methylation data of other additional 15 cancers
types were also extracted from the TCGA (see Additional
file 1). Finally, DNA methylation data recently generated by
Luo et al. [36] using the HumanMethylation450K array in
19 colon mucosae from healthy individuals, 22 adjacent
non-tumor tissues, 42 adenomas, and 64 carcinomas were
also included.
Cell lines used in the study are described in Additional
file 1.Gene expression analysis
For the preliminary analysis, total RNA was extracted from
tissues and cell lines and quantified by real-time PCR, ap-
plying the delta Ct method (primers are listed in Additional
file 1: Table S6). Expression analysis of the Colonomics
series was performed as described [58]. Both raw and nor-
malized data are available in the Gene Expression Omnibus
(GEO) database with accession number GSE44076.DNA methylation analysis
Genomic DNA of five cell lines, tumors, and adjacent
mucosae from 64 patients was treated with the EZ DNA
Methylation™ Kit (Zymo Research) to evaluate their
methylation status by bisulfite sequencing and dissoci-
ation curve analysis as described [59] (primers are listed
in Additional file 1: Table S7). Samples were analyzed in
triplicates.
Methylation data in the Colonomics series was collected
with Infinium HumanMethylation450 array. Further de-
tails are available as Additional file 1.
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ANOVA was applied to determine the significant differ-
ences between three groups of samples (normal mucosae,
adjacent tissue, and CRC tumors) for both gene expres-
sion and DNA methylation. Genes with statistically signifi-
cant differences (P < 0.05) were further evaluated using
the Tukey’s HSD (honest significant difference) test
(Table 2).
Wilcoxon test was applied to set differences between clin-
ical variables and gene expression and DNA methylation of
Colonomics data. Adjusted p value was obtained using
Benjamin and Hochberg method (Additional file 1:
Table S3 and S4).
Free and overall survival analysis was performed for
both gene expression and DNA methylation data using
tertiles. A log-rank univariate test was performed for
each gene and a Kaplan-Meier curve was built. Only
genes with a P value <0.2 in the univariate analysis were
considered for the multivariate analysis. Finally, with
these genes, a Cox Proportional Hazards model was
built.
Hierarchical clustering was performed using the Ward
method with euclidean distances. We set the number of
clusters to 3 to see how well the three types of tissues are
classified. The Jaccard similarity index was obtained by
bootstrap resampling to assess the stability of the clusters.
A valid, stable cluster should yield a mean Jaccard similarity
value of 0.75 or more.
Additional file
Additional file 1: Supplementary information. Supplementary
methods, supplementary references, Tables S1–S7, and Figures S1–S5.
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